ong-term effects of ipragliflozin on diabetic nephropathy and blood pressure in patients with type 2 diabetes
Not Applicable
Completed
- Conditions
- Type 2 diabetes with diabetic nephropathy
- Registration Number
- JPRN-UMIN000031157
- Lead Sponsor
- Ogawa Red Cross Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients who have history or current serious diabetic complication. 2. Patients that insulin dependence is suspected. 3. Patients who have history or current cardiac failure (New York Heart Association Class III or IV), myocardial infarction or cerebrovascular disorder. 4. Patients whose eGFR lower than 45 mL/min/1.73m2, serum creatinine higher than 1.5 mg/dL. 5. Patients who have hepatic dysfunction.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in HbA1c
- Secondary Outcome Measures
Name Time Method Changes from baseline in urinary albumin-to-creatinine ratio (UACR), eGFR, blood pressure, body weight, fasting plasma glucose, fasting serum lipids, AST, ALT, and uric acid at week 104.